Strategy meets execution for MedTech, Pharma & Health Ingredients.
Q22 helps organisations turn complex strategies into commercial results across Europe, from market entry and business development to venture building and partnerships.
From strategy to lasting impact.
Q22 combines strategic insight with hands-on execution to unlock growth, build ventures and accelerate commercial performance in regulated healthcare markets.
Interim Business Development
Senior commercial leadership to drive growth, positioning and market expansion.
→EU Market Entry
Navigate regulations, partners, setup and markets with confidence.
→Venture Building
From concept to credible company building in MedTech, Pharma and Health Ingredients.
→Strategic Partnerships
Create and manage partnerships that deliver commercial and strategic value.
→Commercial Acceleration
Optimise go-to-market execution and unlock sustainable growth.
→
Real challenges. Real impact.
Q22 works where strategy, regulation, commercial traction and execution meet.
Built for organisations that need more than advice.
Q22 is led by Ivo Schefman, a senior commercial and business development leader with experience across medical nutrition, pharma, biomaterials, MedTech, drug delivery, ingredients, venture building and European market development.
Partnerships that create lasting value for patients and businesses.
Q22 is a strategic partner for organisations that want more than advice, they want results.
Let’s connect